Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer

Abstract

Bevacizumab and Tamoxifen are valid therapeutic options for metastatic breast cancer (mBC) patients. In this report, we describe a 47 year old woman with mBC successfully treated with a maintenance therapy with Bevacizumab+Tamoxifen. A maintenance approach using 2 different drugs with different targets and mechanism of action, such as anti-angiogenic and anti-hormonal treatment is particularly intriguing because they affect different pathways involved in mBC progression. Further studies including a large number of patients are needed, in order to select women who could benefit from this maintenance approach.

Keywords:

• bevacizumab
• metastatic breast cancer
• maintenance therapy
• tamoxifen

Ethical Review

Ethical approval was obtained from the ethics committee of the University of Siena. Written informed consent was obtained from the patient for publication of this case report.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.